Product Description
CACIPLIQ20 is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates.
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Organ, Tissue, Regeneration, Repair and Replacement
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain|Chronic Pain|Edema|Facial Pain|Keloid|Skin Ulcer|Wounds, Stab
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05528328 |
MATRISCAR | P3 |
Recruiting |
Wounds, Stab|Acute Pain|Chronic Pain|Skin Ulcer|Keloid|Facial Pain|Edema |
2024-10-01 |
2024-02-14 |
Primary Endpoints |